

AEGIS Clinical Trial

The primary goal of HCV therapy is viral elimination. The secondary goal of therapy is to slow down or stop disease progression and improve the patient's quality of life. In clinical trials, viral elimination has been shown to halt disease progression and improve the histological damage caused by hepatitis C. Research has recently shown that improvement in liver histology occurs even in people who do not eliminate the hepatitis C virus.

A new clinical trial study is now being conducted and patients are now being recruited in order to evaluate the safety and effectiveness of two different doses of gamma interferon (InterMune) on the reduction of liver fibrosis in adults infected with hepatitis C who have a significant risk of developing the complications of advanced liver disease.

Study participants in this trial will be required to undergo a medical history screening, physical examination, various laboratory tests and a liver biopsy, unless one has been performed within the last 12 months. Eligible participants will be randomly assigned to receive one of two doses of gamma interferon or a placebo. At the end of this study, patients who were assigned to the placebo group will be offered the opportunity to receive gamma interferon in a follow-up study if the data from this study indicates that the drug is safe and effective.

If you would like to learn more about this study or a study location near you, please call 866-618-4634 (toll free).

Clinical Trial Locations

Canada

Province	City
Alberta	Calgary
Ontario	Toronto

United States

State / District / Territory	City
Arizona	Scottsdale Tucson
California	Chula Vista La Jolla Loma Linda Los Angeles Orange Pasadena Sacramento San Francisco
Colorado	Denver
Connecticut	West Haven Farmington
Florida	Gainesville Miami
Georgia	Atlanta
Illinois	Chicago

Indiana	Indianapolis
Louisiana	New Orleans
Maryland	Baltimore
Massachusetts	Boston Worcester
Michigan	Royal Oak
Minnesota	Minneapolis Rochester St. Paul
Missouri	St. Louis
New Mexico	Albuquerque
New York	Bronx Manhasset New York City Syracuse
New Mexico	Albuquerque
North Carolina	Chapel Hill Charlotte Durham
Ohio	Cincinnati Cleveland
Pennsylvania	Philadelphia Pittsburgh
Puerto Rico	Santruce
Texas	Dallas Galveston Houston
Virginia	Fairfax Falls Church Richmond
Washington	Seattle
Washington D.C.	Washington DC

August 2002